{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:20Z","timestamp":1740108320865,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00228-023-03553-w","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:02:08Z","timestamp":1695427328000},"page":"1623-1630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential inhibition of platelet function by cilostazol in combination with clopidogrel"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-7974","authenticated-orcid":false,"given":"Masako","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Dahlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,23]]},"reference":[{"key":"3553_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/jscd.2000.7216","volume":"9","author":"F Goto","year":"2000","unstructured":"Goto F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y (2000) Cilostazol stroke prevention study: A placebo controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9:147\u2013157. https:\/\/doi.org\/10.1053\/jscd.2000.7216","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"3553_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","volume":"9","author":"Y Shinohara","year":"2010","unstructured":"Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C, CSPS 2 group (2010) Cilostazol for prevention of secondary stroke (CSPS2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:959\u2013968. https:\/\/doi.org\/10.1016\/S1474-4422(10)70198-8","journal-title":"Lancet Neurol"},{"key":"3553_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","volume":"18","author":"Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, on behalf of the CSPS.com Trial Investigators","year":"2019","unstructured":"Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, on behalf of the CSPS.com Trial Investigators (2019) Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 18:539\u2013548. https:\/\/doi.org\/10.1016\/S1474-4422(19)30148-6","journal-title":"Lancet Neurol"},{"key":"3553_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","volume":"19","author":"Y Liu","year":"2001","unstructured":"Liu Y, Shakur Y, Yoshitake M, Kambayashi J (2001) Cilostazol (Pletal\u00ae): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19:369\u2013386. https:\/\/doi.org\/10.1111\/j.1527-3466.2001.tb00076.x","journal-title":"Cardiovasc Drug Rev"},{"key":"3553_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0049-3848(98)00172-8","volume":"93","author":"T Inoue","year":"1999","unstructured":"Inoue T, Sohma R, Morooka S (1999) Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thromb Res 93:137\u2013143. https:\/\/doi.org\/10.1016\/S0049-3848(98)00172-8","journal-title":"Thromb Res"},{"key":"3553_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0049-3848(00)00415-1","volume":"101","author":"H Kariyazono","year":"2001","unstructured":"Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K (2001) Inhibition of platelet aggregation and the release of p-selectin from platelets by cilostazol. Thromb Res 101:445\u2013453. https:\/\/doi.org\/10.1016\/S0049-3848(00)00415-1","journal-title":"Thromb Res"},{"key":"3553_CR7","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1253\/circj.CJ-08-0289","volume":"72","author":"H Yamamoto","year":"2008","unstructured":"Yamamoto H, Takahashi K, Watanabe H, Yoshikawa Y, Shirakawa R, Higashi T, Kawato M, Ikeda T, Tabuchi A, Morimoto T, Kita T, Horiuchi H (2008) Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. Circ J 72:1844\u20131851. https:\/\/doi.org\/10.1253\/circj.CJ-08-0289","journal-title":"Circ J"},{"key":"3553_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.thromres.2012.05.030","volume":"130","author":"K Satoh","year":"2012","unstructured":"Satoh K, Fukasawa I, Kanemaru K, Yoda S, Kimura Y, Inoue O, Ohta M, Kinouchi H, Ozaki Y (2012) Platelet aggregometry in the presence of PGE1 provides a reliable method for cilostazol monitoring. Thromb Res 130:616\u2013621. https:\/\/doi.org\/10.1016\/j.thromres.2012.05.030","journal-title":"Thromb Res"},{"key":"3553_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/09537104.2010.525976","volume":"22","author":"J Yamanouchi","year":"2011","unstructured":"Yamanouchi J, Hato T, Niiya T, Nakagawa K, Kumon Y, Fujiwara H, Yakushijin Y, Yasukawa M (2011) Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol. Platelets 22:135\u2013142. https:\/\/doi.org\/10.3109\/09537104.2010.525976","journal-title":"Platelets"},{"key":"3553_CR10","doi-asserted-by":"publisher","unstructured":"Geiger J, Brich J, H\u00f6nig-Liedl P, Eigenthaler M, Schanzenb\u00e4cher P, Herbert JM, Walter U (2007) Specific impairment of human platelet P2Y(AC)ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Vasc Biol 7:249\u201352.\u00a0https:\/\/doi.org\/10.1161\/01.atv.19.8.2007","DOI":"10.1161\/01.atv.19.8.2007"},{"key":"3553_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.amjcard.2007.03.070","volume":"100","author":"BK Lee","year":"2007","unstructured":"Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH, Lee CW, Hong MK, Kim JJ, Jang S, Chi HS, Park SJ (2007) Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and p-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 100:610\u2013614. https:\/\/doi.org\/10.1016\/j.amjcard.2007.03.070","journal-title":"Am J Cardiol"},{"key":"3553_CR12","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1093\/eurheartj\/ehn287","volume":"29","author":"DJ Angiolillo","year":"2008","unstructured":"Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Bass GLA (2008) A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29:2202\u20132211. https:\/\/doi.org\/10.1093\/eurheartj\/ehn287","journal-title":"Eur Heart J"},{"key":"3553_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","volume":"53","author":"YH Jeong","year":"2009","unstructured":"Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, Hwang JY, Park SW (2009) Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity. Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study. J Am Coll Cardiol 53:1101\u20131109. https:\/\/doi.org\/10.1016\/j.jacc.2008.12.025","journal-title":"J Am Coll Cardiol"},{"key":"3553_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijs.12420","volume":"10","author":"Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T, for the CSPS.com Study Investigators","year":"2015","unstructured":"Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T, for the CSPS.com Study Investigators (2015) Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. Int J Stroke 10:253\u2013258. https:\/\/doi.org\/10.1111\/ijs.12420","journal-title":"Int J Stroke"},{"key":"3553_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0049-3848(01)00350-4","volume":"104","author":"M Yamazaki","year":"2001","unstructured":"Yamazaki M, Uchiyama S, Iwata M (2001) Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 104:197\u2013205. https:\/\/doi.org\/10.1016\/S0049-3848(01)00350-4","journal-title":"Thromb Res"},{"key":"3553_CR16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/jth.13391","volume":"14","author":"M Yamazaki","year":"2016","unstructured":"Yamazaki M, Ohnishi T, Hosokawa K, Yamaguchi K, Yoneyama T, Kawashima A, Okada Y, Kitagawa K, Uchiyama S (2016) Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. J Thromb Haemost 14:1788\u20131797. https:\/\/doi.org\/10.1111\/jth.13391","journal-title":"J Thromb Haemost"},{"key":"3553_CR17","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1309\/LMJF9WK85YAAAEYV","volume":"44","author":"RG Fisher","year":"2013","unstructured":"Fisher RG, Teitel ER, Yee AT, Chuang AZ (2013) Evaluation of the effectiveness of the AggreGuide A-100 in measuring platelet aggregation in individuals taking a high or low dose of aspirin. Lab Medicine 44:e83\u2013e91. https:\/\/doi.org\/10.1309\/LMJF9WK85YAAAEYV","journal-title":"Lab Medicine"},{"key":"3553_CR18","doi-asserted-by":"publisher","unstructured":"Madhavi R, Rajasekhar D, Vanajakshamma V, Reddy GO, Kapil C, Sowjenya G (2018) Variability in antiplatelet drugs\u2019 response in Indian patients undergoing percutaneous coronary intervention and outcome modification by tailored antiplatelet therapy. J Cardiol Cardiovasc Ther 9:555762. https:\/\/doi.org\/10.19080\/JOCCT.2018.09.555762","DOI":"10.19080\/JOCCT.2018.09.555762"},{"key":"3553_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.mvr.2011.11.007","volume":"83","author":"K Hosokawa","year":"2012","unstructured":"Hosokawa K, Ohnishi T, Fukasawa M, Kondo T, Sameshima H, Koide T, Tanaka K, Maruyama I (2012) A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res 83:154\u2013161. https:\/\/doi.org\/10.1016\/j.mvr.2011.11.007","journal-title":"Microvasc Res"},{"key":"3553_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1160\/TH12-06-0441","volume":"109","author":"K Hosokawa","year":"2013","unstructured":"Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I (2013) Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 109:102\u2013111. https:\/\/doi.org\/10.1160\/TH12-06-0441","journal-title":"Thromb Haemost"},{"key":"3553_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2169\/internalmedicine.50.4623","volume":"50","author":"H Maruyama","year":"2011","unstructured":"Maruyama H, Takeda H, Dembo T, Nagoya H, Kato Y, Fukuoka T, Deguchi I, Horiuchi Y, Tanahashi N (2011) Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic atroke or carotid artery stenting using the VerifyNow P2Y12 assay. Intern Med 50:695\u2013698. https:\/\/doi.org\/10.2169\/internalmedicine.50.4623","journal-title":"Intern Med"},{"key":"3553_CR22","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1160\/TH13-10-0856","volume":"111","author":"HA KhannaV","year":"2014","unstructured":"KhannaV HA, Mikael R, Sambu N, Englyst N, Curzen N (2014) Does the VerifyNow P2Y12 assay overestimate \u201ctherapeutic response\u201d to clopidogrel? Insights using short thrombelastography Thromb Haemost 111:1150\u20131159. https:\/\/doi.org\/10.1160\/TH13-10-0856","journal-title":"Insights using short thrombelastography Thromb Haemost"},{"key":"3553_CR23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1161\/STROKEAHA.118","volume":"50","author":"M Bieber","year":"2019","unstructured":"Bieber M, Schuhmann MK, Volz J, Kumar GJ, Vaidya JR, Nieswandt B, Pham M, Stoll G, Kleinschnitz C, Kraft P (2019) Description of a novel phosphodiesterase (PDE)-3 Inhibitor protecting mice from ischemic stroke independent from platelet function. Stroke 50:478\u2013486. https:\/\/doi.org\/10.1161\/STROKEAHA.118","journal-title":"Stroke"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03553-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:02:53Z","timestamp":1700596973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03553-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,23]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03553-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2023,9,23]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the ethics standards of Tokyo Women\u2019s Medical University and the Declaration of Helsinki. This study was approved by the Tokyo Women\u2019s Medical University Ethics Committee (approval number 160808). Written informed consent was obtained from all subjects prior to participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TO and KH are employees of Fujimori Kogyo Co., Ltd. JD has received consulting fees from Fujimori Kogyo Co., Ltd. and Aggredyne, Inc. KK received lecture fees and a research grant from Otsuka Pharmaceutical Co. Ltd. and Sanofi Co. The other authors state that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}